Related Experiment Videos
Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation
Markus G Seidel1, Gerhard Fritsch, Susanne Matthes-Martin
1St. Anna Children's Hospital and Children's Cancer Research Institute (CCRI), Vienna, Austria. Markus.Seidel@stanna.at
Insights
Rabbit-derived antithymocyte globulin (ATG) dose impacts outcomes in pediatric allogeneic hematopoietic stem cell transplantation (HSCT). Low-dose ATG is recommended to reduce EBV-linked disease and fatal infections.
Area of Science:
- Immunology
- Hematology
- Pediatric Transplantation
Background:
- Allogeneic hematopoietic stem cell transplantation (HSCT) is a critical treatment for pediatric hematologic malignancies and other conditions.
- Antithymocyte globulin (ATG) is frequently used for T-cell depletion to prevent graft-versus-host disease (GVHD) and facilitate engraftment.
- Optimal dosing of rabbit-derived ATG in pediatric HSCT remains an area of investigation.
Purpose of the Study:
- To investigate the dose-dependent effects of rabbit-derived ATG on clinical outcomes in pediatric allogeneic HSCT.
- To correlate ATG serum levels and cumulative doses with the incidence of GVHD, rejection, viral infections, and survival.
- To establish evidence-based recommendations for ATG dosing in this vulnerable population.
Main Methods:
- Serum ATG levels were monitored in 32 pediatric and adolescent patients undergoing allogeneic HSCT.
- Patients received varying cumulative doses of rabbit-derived ATG (7.5–40 mg/kg).
- Incidence of acute/chronic GVHD, rejection, viral infections, EBV-lymphoproliferative disease, and overall survival were analyzed in relation to ATG dose.
Main Results:
- Cumulative ATG doses of 7.5–20 mg/kg demonstrated a constant half-life and linear dose-Cmax correlation.
- Higher ATG doses (30–40 mg/kg) resulted in drug accumulation.
- High-dose ATG did not improve GVHD prevention but significantly increased EBV-linked disease, viral infections, and rejection rates, impacting survival.
Conclusions:
- High-dose rabbit-derived ATG is not beneficial and is associated with increased risks of severe complications in pediatric HSCT.
- A low-dose ATG regimen is strongly supported for use in pediatric allogeneic HSCT to improve safety and outcomes.
- Optimizing ATG dosing is crucial for mitigating adverse events and enhancing survival post-transplant.
Abstract:
To analyze the dose effects of rabbit-derived antithymocyte globulin (ATG) in children after allogeneic hematopoietic stem cell transplantation (HSCT), ATG serum levels were monitored in 32 children and adolescents (median age 3.42 years, range 0.34-18.67 years) and the incidence of acute and chronic graft-versus-host disease, rejection, viral infections, EBV-lymphoproliferative disease, and survival was correlated with the ATG dose used. Cumulative doses from 7.5 to 20 mg/kg showed a constant half-life and linear correlation between dose and Cmax, whereas higher doses (30-40 mg/kg) accumulated in the body. High-dose ATG is of no benefit for preventing graft-versus-host disease but is associated with a significant increase in EBV-linked disease, and it appears to enhance the susceptibility to fatal viral infections and rejection. These data strongly support the use of a low-dose ATG regimen in pediatric HSCT.